References in the O-GlcNAc Database

Lin CH, Liao CC, Wang SY, Peng CY, Yeh YC, Chen MY, Chou TY. Comparative O-GlcNAc Proteomic Analysis Reveals a Role of O-GlcNAcylated SAM68 in Lung Cancer Aggressiveness. Cancers 2022 14(1) 35008409

Abstract:
O-GlcNAcylation is a reversible and dynamic post-translational protein modification catalyzed by O-GlcNAc transferase (OGT). Despite the reported association of O-GlcNAcylation with cancer metastasis, the O-GlcNAc proteome profile for cancer aggressiveness remains largely uncharacterized. Here, we report our comparative O-GlcNAc proteome profiling of two differentially invasive lung adenocarcinoma cell lines, which identified 158 down-regulated and 106 up-regulated candidates in highly invasive cells. Among these differential proteins, a nuclear RNA-binding protein, SAM68 (SRC associated in mitosis of 68 kDa), was further investigated. Results showed that SAM68 is O-GlcNAcylated and may interact with OGT in the nucleus. Eleven O-GlcNAcylation sites were identified, and data from mutant analysis suggested that multiple serine residues in the N-terminal region are important for O-GlcNAcylation and the function of SAM68 in modulating cancer cell migration and invasion. Analysis of clinical specimens found that high SAM68 expression was associated with late cancer stages, and patients with high-OGT/high-SAM68 expression in their tumors had poorer overall survival compared to those with low-OGT/low-SAM68 expression. Our study revealed an invasiveness-associated O-GlcNAc proteome profile and connected O-GlcNAcylated SAM68 to lung cancer aggressiveness.

O-GlcNAc proteins:
A0A024R7P5, A0A024R9E2, A0A087WWU8, A0A0A0MTS7, SHOT1, A8K3C3, A8K9J7, B7Z2Z8, B7Z596, D3DS63, E7ETM0, E7EVA0, F8VR77, H0YN18, H3BPE1, K7ERG4, PSD12, DFFA, PLOD2, PSDE, BIN1, TCRG1, ML12B, HGS, HNRDL, RPAC1, P4HA2, HNRPR, PLRG1, ZN207, BUB3, ACTN4, KDM1A, PLOD3, CPNE3, FLNB, NU155, GLRX3, MTA2, SC31A, UBE4B, TFR1, ANXA1, HSPB1, ITB1, DCUP, GELS, ENOA, NPM, TPM3, LDHB, ANXA2, TBB5, HNRPC, TPM2, ANXA6, 4F2, VIME, ANXA5, RSSA, ENOG, TPM1, PARP1, UBB, UBC, CH60, ACADM, G6PD, PCNA, KCRB, KCRU, ACTN1, XRCC6, EF2, KAP2, SYDC, AMPN, EZRI, NAGAB, HMGA1, ML12A, AOC1, ICAL, VATB2, FLNA, OSBP1, UBA1, GCSH, PSA1, PSA3, SYVC, TPP2, CLIP1, HNRH3, KINH, HSP74, RADI, MYH9, MYH10, ACTN2, ADDA, FUS, MYH11, RL4, ODO2, VATA, CAP2, GARS, MSH2, PRS6B, UBP5, RS9, MAP1B, IQGA1, KC1A, NASP, FAS, SYAC, NU153, HDGF, ACLY, SYYC, RD23A, PSMD4, TERA, EIF3B, IF6, PSA6, RS3A, HNRPK, 1433G, PP1B, PRS8, RL7A, PP2AB, RS6, RL10A, RS27A, RL40, 2ABA, TPM4, EF1A1, GTF2I, RAE1L, HNRPU, SPTB2, EWS, PLCB3, FKBP4, IF4G1, SSBP, 1433F, PUR1, PRDX1, KHDR1, ACTN3, PP2BA, ILF2, ACACA, CBX3, G3BP1, EIF3I, DC1I2, ROCK1, HDAC1, CUL1, NACA, SPTN1, SMC1A, GANAB, PSME4, SYK, PLEC, PP1R7, SC23A, SC23B, TSN, CIP4, MARE1, DDB1, CART, RBBP7, ACTBL, ST1C3, P4R3A, Q6IPH7, C2D1A, POTEE, SND1, CYFP1, MON2, MYH14, CAND1, ABCA7, LRC47, THMS1, CPSF7, GT251, SERB1, ABCF1, Q8TDJ5, Q8WWH9, AGRV1, TCPW, TFG, STAM1, SNR40, VPS35, SIN3A, NIBA2, PSB7, TSNAX, DHRS6, RBM4, XRN2, SPTN4, SLK, MYG1, XPP1, UGGG1, CPSF2, NAGK, NUDT5, PRP19, UBQL1, PACN2, SNX6, NCKP1, HYOU1, LSM4, SNX5, S23IP, V9HVZ7, V9HW77

Species: Homo sapiens

Download

BIB

JSON

CSV

XLSX

Champattanachai V, Netsirisawan P, Chaiyawat P, Phueaouan T, Charoenwattanasatien R, Chokchaichamnankit D, Punyarit P, Srisomsap C, Svasti J. Proteomic analysis and abrogated expression of O-GlcNAcylated proteins associated with primary breast cancer. Proteomics 2013 13(14) 23576270

Abstract:
O-GlcNAcylation is a dynamic PTM of nuclear and cytoplasmic proteins, regulated by O-GlcNAc transferase (OGT) and O-GlcNAcase, which catalyze the addition and removal of O-GlcNAc, respectively. This modification is associated with glucose metabolism, which plays important roles in many diseases including cancer. Although emerging evidence reveals that some tumor-associated proteins are O-GlcNAc modified, the total O-GlcNAcylation in cancer is still largely unexplored. Here, we demonstrate that O-GlcNAcylation was increased in primary breast malignant tumors, not in benign tumors and that this augmentation was associated with increased expression of OGT level. Using 2D O-GlcNAc immnoblotting and LC-MS/MS analysis, we successfully identified 29 proteins, with seven being uniquely O-GlcNAcylated or associated with O-GlcNAcylation in cancer. Of these identified proteins, some were related to the Warburg effect, including metabolic enzymes, proteins involved in stress responses and biosynthesis. In addition, proteins associated with RNA metabolism, gene expression, and cytoskeleton were highly O-GlcNAcylated or associated with O-GlcNAcylation. Moreover, OGT knockdown showed that decreasing O-GlcNAcylation was related to inhibition of the anchorage-independent growth in vitro. These data indicate that aberrant protein O-GlcNAcylation is associated with breast cancer. Abnormal modification of these O-GlcNAc-modified proteins might be one of the vital malignant characteristics of cancer.

O-GlcNAc proteins:
AXA2L, TRFE, G3P, K1C18, VIME, K2C7, RSSA, ENOG, HSP7C, KPYM, TYPH, VDAC1, ROA2, PRDX6, PRDX3, 2AAA, HNRPF, TPIS, ACTB, HNRPK, PRDX4, PDIA6, HNRL2, FUBP1, PARK7